News
VTGN
--
0.00%
--
BioMedNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) Presents Data Regarding Drug Candidate for Replacement of Addictive Benzodiazepines
Mar 22, 2021 (Investor Brand Network via COMTEX) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines...
Investor Brand Network · 03/22 17:26
VistaGen Therapeutics Says Co's Poster Presentation At Anxiety And Depression Association Of America 2021 Conference 'Differentiates PH94B's Mechanism Of Action From Highly-Addictive Benzodiazepines'
VistaGen Therapeutics, Inc. (NASDAQ:VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and
Benzinga · 03/22 12:39
VistaGen's Poster Presentation at the Anxiety and Depression Association of America's 2021 Annual Conference Differentiates PH94B's Mechanism of Action from Highly-Addictive Benzodiazepines
VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disord...
GlobeNewswire · 03/22 12:30
BioMedNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation Schedule for Upcoming March Investor Conferences
Mar 16, 2021 (Investor Brand Network via COMTEX) -- VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the...
Investor Brand Network · 03/16 16:25
VistaGen Therapeutics to Participate in Upcoming Investor Conferences in March
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous syste...
GlobeNewswire · 03/16 11:48
VistaGen Therapeutics files for $250M mixed shelf
VistaGen Therapeutics (VTGN) has filed a prospectus for a mixed shelf offering of up to $250M.The filing does not necessarily indicate that a sale has begun, or will occur in
Seekingalpha · 03/16 06:52
BRIEF-Vistagen Therapeutics Files For Mixed Shelf Of Upto $250 Mln
reuters.com · 03/15 21:54
BioMedNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Preclinical Data Demonstrating Differentiated Mechanism of Action of PH10 from Benzodiazepines
Mar 11, 2021 (Investor Brand Network via COMTEX) -- VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety,...
Investor Brand Network · 03/11 15:26
BRIEF-VistaGen Says Co's PH10 Nasal Spray Demonstrates Different Mechanism Of Action
reuters.com · 03/11 13:56
DJ VistaGen: PH10 Nasal Spray Shows Standalone Potential in Depression Disorders >VTGN
Dow Jones · 03/11 13:51
VistaGen Reports Its PH10 Nasal Spray Showed Different Mechanism Of Action From Benzodiazepines In Preclinical Study
VistaGen Therapeutics, Inc. (NASDAQ:VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety,
Benzinga · 03/11 13:37
VistaGen's PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study
SOUTH SAN FRANCISCO, Mar 11, 2021 (GLOBE NEWSWIRE via COMTEX) -- SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc....
GlobeNewswire · 03/11 13:30
New Strong Sell Stocks for March 11th
Zacks.com · 03/11 13:17
BioMedNewsBreaks - VistaGen Therapeutics Inc.'s (NASDAQ: VTGN) Pipeline Holds Potential to Go Beyond Standard of Care for Anxiety, Depression
Mar 04, 2021 (Investor Brand Network via COMTEX) -- VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing a new...
Investor Brand Network · 03/04 19:15
Penny Stocks To Buy With Analysts Targeting 76%-209% Upside
Feb 24, 2021 (Penny Stocks via COMTEX) -- Analysts Are Bullish On These 4 Penny Stocks We've discussed penny stocks and analyst ratings many times before....
Penny Stocks · 02/24 21:12
The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22)
Benzinga · 02/23 12:25
VistaGen Therapeutics Inc. (NASDAQ: VTGN) Committed to Developing New Generation Alternatives to Current Standard of Care for Anxiety Disorders
Investor Brand Network · 02/22 15:33
AVGR, EBON, LODE and NXTD among midday movers
Gainers: Immunome (IMNM) +120%.Greenland Technologies (GTEC) +119%.Liberty TripAdvisor (LTRPB) +60%.Motus GI Holdings (MOTS) +35%.Charah Solutions (CHRA) +35%.Avinger (AVGR) +34%.VistaGen Therapeutics (VTGN) +32%.U.S. Well Services (USWS) +28%.Ebang Intern...
Seekingalpha · 02/18 17:40
Immunome, Avinger leads healthcare gainers; MEDNAX, ReWalk Robotics among major losers
Gainers: Immunome (IMNM) +93%, Avinger (AVGR) +33%, Titan Pharmaceuticals (TTNP) +17%, GBS (GBS) +15%, VistaGen Therapeutics (VTGN) +15%.Losers: MEDNAX (MD) -23%, ReWalk Robotics (RWLK) -21%, Shineco (TYHT) -19%, Check-Cap (CHEK) -15%, Advaxis (ADXS) -12%.
Seekingalpha · 02/18 16:01
Benzinga's Top Ratings Upgrades, Downgrades For February 18, 2021
Benzinga · 02/18 15:02
Webull provides a variety of real-time VTGN stock news. You can receive the latest news about VistaGen through multiple platforms. This information may help you make smarter investment decisions.
About VTGN
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The company's pipeline includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that is preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that is planning for Phase 2b development as a stand-alone treatment for depressive disorder (MDD), and AV-101 which the Company is developing for the treatment of depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. In addition, the Company has developed a human pluripotent stem cell (hPSC) technology platform, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs).